Ourania Tatsis - Mar 17, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Reg. & Quality Off.
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Mar 17, 2022
Transactions value $
-$708,572
Form type
4
Date filed
3/21/2022, 04:15 PM
Previous filing
Feb 28, 2022
Next filing
Aug 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$700K -2.8K -5.58% $250.10 47.4K Mar 17, 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$8.54K -34 -0.07% $251.24 47.4K Mar 17, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $250.10 (range $250.00 to $250.55).
F3 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.